Showing results (111-120 of 151) with videos related to
Sort By:
Pageof 16
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2025
Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 PatientsTakami Sato, Marcus O Butler, Sophie Piperno-Neumann, et al.Clinical and Translational Science|February 16, 2024
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumorsDebbie Robbrecht, Jean-Jacques Grob, Oliver Bechter, et al.Current Oncology (Toronto, Ont.)|April 26, 2024
Access to Oncology Medicines in Canada: Consensus Forum for Recommendations for ImprovementSandeep R Sehdev, Nigel S B Rawson, Olexiy I Aseyev, et al.Journal for Immunotherapy of Cancer|June 15, 2022
Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumabGeoffrey Alan Watson, Enrique Sanz-Garcia, Wen-Jiang Zhang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2020
PD-1 Blockade in Anaplastic Thyroid CarcinomaJaume Capdevila, Lori J Wirth, Thomas Ernst, et al.Cancer|January 9, 2020
Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMsAaron R Hansen, Kari Ala-Leppilampi, Chris McKillop, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2025
Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic MelanomaReinhard Dummer, Shahneen Sandhu, Wilson H Miller, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2020
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86)Neesha C Dhani, Hal W Hirte, Lisa Wang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2023
Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical TrialAbdulazeez Salawu, Ben X Wang, Ming Han, et al.Cell Reports. Medicine|March 9, 2024
Ex vivo activation of the GCN2 pathway metabolically reprograms T cells, leading to enhanced adoptive cell therapyMichael St Paul, Samuel D Saibil, Meghan Kates, et al.Pageof 16